成人隐匿性自身免疫糖尿病与2型糖尿病微血管并发症风险的时变差异:英国前瞻性糖尿病研究30年随访数据的事后分析(UKPDS 86)
该研究对UKPDS 30年随访数据事后分析,纳入5028例参与者,其中564例成人隐匿性自身免疫糖尿病(LADA)、4464例2型糖尿病。中位随访17.3年,LADA前9年复合微血管结局风险低于2型糖尿病(校正HR 0.45),后续年份风险高于2型糖尿病(校正HR 1.25),校正更新的9年平均HbA1c后后续风险增加完全解释(校正HR 0.99)。
要点
- LADA前9年复合微血管结局风险低于2型糖尿病(校正HR 0.45,95%CI 0.30-0.68)。
- LADA后续年份复合微血管结局风险高于2型糖尿病(校正HR 1.25,95%CI 1.01-1.54)。
- 校正更新的9年平均HbA1c后,LADA后续风险增加完全解释(校正HR 0.99,95%CI 0.80-1.23)。
核心结论
- LADA成人起病时微血管并发症风险低于2型糖尿病,但随后风险更高,继发于更差的血糖控制。
- 从诊断时即实施严格血糖控制或可降低LADA成人后续微血管并发症风险。
研究设计与样本
- UKPDS 30年随访数据的事后分析(UKPDS 86),纳入有糖尿病自身抗体检测且无既往微血管事件的参与者。
- 至少一种可检测自身抗体者为LADA,所有自身抗体均阴性者为2型糖尿病。
- 共纳入5028例参与者,其中LADA 564例,2型糖尿病4464例;随访截至2007年9月30日。
- 中位随访17.3年(IQR 12.6-20.7)。
主要发现
- 复合微血管结局共发生在1041例(21%)参与者中。
- LADA复合微血管结局发生率为15.8(95%CI 13.4-18.7)/1000人年,2型糖尿病为14.2(95%CI 13.3-15.2)/1000人年。
- 前9年随访LADA复合结局风险低于2型糖尿病(校正HR 0.45,95%CI 0.30-0.68,p<0.0001)。
- 后续年份LADA复合结局风险高于2型糖尿病(校正HR 1.25,95%CI 1.01-1.54,p=0.047)。
- 校正LADA较2型糖尿病更高的更新9年平均HbA1c后,LADA后续复合微血管结局风险增加完全解释(校正HR 0.99,95%CI 0.80-1.23,p=0.93)。
临床怎么用
- 作者认为,从诊断时即实施严格血糖控制或可降低LADA成人后续微血管并发症风险。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Latent autoimmune diabetes of adulthood (LADA) differs in clinical features from type 2 diabetes. Whether this difference translates into different risks of complications remains controversial. We examined the long-term risk of microvascular complications in people enrolled in the UK Prospective Diabetes Study (UKPDS), according to their diabetes autoimmunity status. METHODS: We did a post-hoc analysis of 30-year follow-up data from UKPDS (UKPDS 86). UKPDS participants with diabetes autoantibody measurements available and without previous microvascular events were included. Participants with at least one detectable autoantibody were identified as having latent autoimmune diabetes, and those who tested negative for all autoantibodies were identified as having type 2 diabetes. The incidence of the primary composite microvascular outcome (first occurrence of renal failure, renal death, blindness, vitreous haemorrhage, or retinal photocoagulation) was compared between adults with latent autoimmune diabetes and those with type 2 diabetes. The follow-up ended on Sept 30, 2007. Baseline and updated 9-year mean values of potential confounders were tested in Cox models to adjust hazard ratios (HRs). UKPDS is registered at the ISRCTN registry, 75451837. FINDINGS: Among the 5028 participants included, 564 had latent autoimmune diabetes and 4464 had type 2 diabetes. After median 17·3 years (IQR 12·6-20·7) of follow-up, the composite microvascular outcome occurred in 1041 (21%) participants. The incidence for the composite microvascular outcome was 15·8 (95% CI 13·4-18·7) per 1000 person-years in latent autoimmune diabetes and 14·2 (13·3-15·2) per 1000 person-years in type 2 diabetes. Adults with latent autoimmune diabetes had a lower risk of the composite outcome during the first 9 years of follow-up than those with type 2 diabetes (adjusted HR 0·45 [95% CI 0·30-0·68], p<0·0001), whereas in subsequent years their risk was higher than for those with type 2 diabetes (1·25 [1·01-1·54], p=0·047). Correcting for the higher updated 9-year mean HbA1c seen in adults with latent autoimmune diabetes than in those with type 2 diabetes explained entirely their subsequent increased risk for the composite microvascular outcome (adjusted HR 0·99 [95% CI 0·80-1·23], p=0·93). INTERPRETATION: At diabetes onset, adults with latent autoimmune diabetes have a lower risk of microvascular complications followed by a later higher risk of complications than do adults with type 2 diabetes, secondary to worse glycaemic control. Implementing strict glycaemic control from the time of diagnosis could reduce the later risk of microvascular complications in adults with latent autoimmune diabetes. FUNDING: European Foundation for the Study of Diabetes Mentorship Programme (AstraZeneca).
引用
- Maddaloni E, Coleman RL, Agbaje O, et al. Time-varying risk of microvascular complications in latent autoimmune diabetes of adulthood compared with type 2 diabetes in adults: a post-hoc analysis of the UK Prospective Diabetes Study 30-year follow-up data (UKPDS 86). Lancet Diabetes Endocrinol. 2020. PMID: 32032540. doi:10.1016/S2213-8587(20)30003-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。